Emergent BioSolutions Inc. (NYSE:EBS) Stock Position Lowered by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lessened its position in Emergent BioSolutions Inc. (NYSE:EBS) by 37.0% in the 2nd quarter, Holdings Channel reports. The fund owned 240,768 shares of the biopharmaceutical company’s stock after selling 141,476 shares during the period. Dimensional Fund Advisors LP’s holdings in Emergent BioSolutions were worth $1,642,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its position in shares of Emergent BioSolutions by 22.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 4,409 shares in the last quarter. CWM LLC boosted its stake in shares of Emergent BioSolutions by 32,706.7% during the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 4,906 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Emergent BioSolutions in the second quarter worth $41,000. Verus Capital Partners LLC purchased a new stake in shares of Emergent BioSolutions during the second quarter worth $68,000. Finally, Avidian Wealth Solutions LLC acquired a new stake in Emergent BioSolutions during the first quarter valued at $33,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Stock Up 3.7 %

Shares of EBS stock opened at $8.76 on Friday. The stock’s 50 day simple moving average is $8.23 and its 200 day simple moving average is $6.69. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.54 and a current ratio of 1.06. Emergent BioSolutions Inc. has a twelve month low of $1.42 and a twelve month high of $15.10. The company has a market capitalization of $459.04 million, a price-to-earnings ratio of -0.80 and a beta of 1.59.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.35). Emergent BioSolutions had a negative net margin of 53.26% and a negative return on equity of 34.38%. The company had revenue of $254.70 million during the quarter, compared to the consensus estimate of $199.47 million. During the same period in the previous year, the business posted ($1.06) earnings per share. As a group, research analysts predict that Emergent BioSolutions Inc. will post -1.3 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Benchmark restated a “buy” rating and issued a $8.00 price objective on shares of Emergent BioSolutions in a report on Friday, August 16th. Rodman & Renshaw reissued a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a research note on Friday, September 13th.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.